Follow
Follow
Follow
Follow

Home
About
- TERMS & CONDITIONS
  - PRIVACY POLICY
- Through the Years: Rebuilding Hemp in Kentucky
Products
Education
CBD BLOG
Testing
Contact Us

Shopping Cart

Your cart is currently empty.

Federal Enforcement Record

1. The FinCEN $80 Million Civil Penalty

On March 6, 2026, FinCEN announced an $80,000,000 civil money penalty against Canaccord Genuity LLC for willful Bank Secrecy Act violations.

The Financial Crimes Enforcement Network assessed what it described as the largest penalty ever imposed against a broker-dealer for violating the Bank Secrecy Act.

The findings: According to FinCEN, Canaccord willfully failed to develop, implement, and maintain an effective anti-money-laundering program, failed to conduct required due diligence on certain foreign correspondent accounts, and failed to file Suspicious Activity Reports. FinCEN’s consent order states that deficient controls allowed high-risk customers, including customers with reported ties to illicit actors and a nexus to Russia and Venezuela, to access the U.S. financial system without appropriate oversight.

The record: FinCEN’s order says Canaccord had repeated notice that its AML program needed significant reform, yet failed to take meaningful corrective action during much of the relevant period. The order further states that when regulators uncovered major flaws, Canaccord personnel altered records and provided false information in an attempt to cover up the violations.

FinCEN News Release

FinCEN Consent Order No. 2026-01 (PDF)

Parallel Securities Action

2. The SEC $20 Million Parallel Settlement

The same day, the SEC announced settled charges against Canaccord Genuity LLC and imposed a $20,000,000 civil penalty tied to the same broader failures.

That same day, the Securities and Exchange Commission announced settled charges against Canaccord Genuity LLC and imposed a $20,000,000 civil penalty. The SEC said the firm failed to file Suspicious Activity Reports in connection with its over-the-counter market-making business.

The impact: The SEC’s order finds that, from February 2019 through March 2022, Canaccord failed to maintain an anti-money-laundering surveillance program reasonably designed to detect, investigate, and report suspicious OTC trading activity. The order states that personnel failed to review or investigate flagged activity, falsified documentation to cover up those failures, and caused the firm to miss approximately 150 SAR filings tied to potentially manipulative or otherwise suspicious trading activity.

Why this matters: The SEC’s order places the problem inside the mechanics of the market itself. It shows that the infrastructure handling low-priced OTC securities was not merely aggressive; federal regulators found that critical monitoring and reporting obligations were not being met.

SEC Administrative Proceeding Summary

SEC Order (PDF)

Note: FinCEN’s consent order also states that payments to the SEC and FINRA would be credited against FinCEN’s penalty in connection with related settlements.

Federal Enforcement Record

The Government’s Words: A Wake-Up Call for Fraud

The nature of this record moves the story beyond a complaint and into black-and-white federal enforcement language. The March 6, 2026 Consent Order does not describe routine compliance slipups. It describes a system in which regulators found that suspicious activity was not properly investigated, critical reports went unreviewed, and records were falsified while illicit actors moved through the market.

Direct quote from FinCEN Director Andrea Gacki:
“Today’s action should be a wake-up call to broker-dealers that willfully fail to comply with their obligations to safeguard the financial system from illicit actors.”

FinCEN said the action was part of Treasury’s broader effort to combat fraud and its harmful effects on the financial markets. In the agency’s telling, this was not an isolated paperwork issue. It was a warning shot about what happens when institutions entrusted with monitoring suspicious activity fail to do the job.

Pump-and-Dump Evidence

The SEC’s order says Canaccord failed to investigate or report suspicious trading activity that included spikes in price and volume consistent with pump-and-dump schemes, cases where a single trader or small group represented a significant share of trading volume in a thinly traded security, and trading surrounding SEC suspensions in low-priced stocks.

Missed SAR Filings

FinCEN said Canaccord failed to file at least 160 SARs, while the SEC’s order says the firm failed to file approximately 150 SARs tied to potentially manipulative or otherwise suspicious trading activity.

Falsified Records

FinCEN’s consent order says two compliance employees falsified records to give the impression reviews had been completed when they had not. The order states that one employee falsified nearly 400 documents in response to FINRA requests.

Illicit Actors

FinCEN said the firm’s customer-due-diligence failures allowed high-risk customers with reported ties to illicit actors, including customers with a nexus to Russia and Venezuela, to access the U.S. financial system without appropriate controls or oversight.

Why This Changes the Framing

This matters because it places the problem inside the mechanics of the market itself. The federal record says the institution responsible for identifying and reporting suspicious activity did not maintain controls that were reasonably designed to do so. That turns market abuse from rumor into a documented enforcement issue.

Page Framing: Linking the Pump to the Grandstanders

Interpretive map for the page: the sequence below is a commentary framework for explaining how lobbying, political messaging, speculative hype, and weak market controls can reinforce one another. Keep this framed as interpretation and analysis, while the federal findings above remain the sourced factual backbone.

The Pump: the page argues that lobbying pressure helped preserve loopholes that expanded the synthetic hemp marketplace.
The Hype: political defense of those loopholes amplified the “Liberty” narrative and helped legitimize the broader market story.
The Dump: the federal record shows suspicious low-priced OTC trading patterns, including pump-and-dump indicators, within the same broader speculative environment.
The Flush: FinCEN and the SEC say Canaccord’s systems failed to properly investigate and report suspicious activity, while records were falsified to conceal review failures.

Official Source Links

FinCEN News Release

FinCEN Consent Order No. 2026-01 (PDF)

SEC Administrative Proceeding Summary

SEC Order (PDF)

Suggested publishing note: keep the federal findings presented as documented agency findings, and present any broader political or industry linkage as commentary or interpretation.

The data below represents more than just a trend; it is a forensic map of a medical emergency created by the “Miller Loophole.” While the Grandstanders in Washington were busy harvesting YouTube clips, Kentucky hospitals were left harvesting the fallout. These figures reflect the documented price of a “Liberty” brand that chose donor checks over DNA safety. Just as important, these numbers are recent. They do not yet include older data from 2018 and 2019, which will be added as the record is expanded. In other words, this is not the full ledger—it is the current documented picture, with earlier years still to come. Check back as additional records are published and the timeline becomes even harder to ignore.

Exhibit Locker: Human Cost

The Forensic Record of Synthetic Deception (2018-2026)

EXHIBIT 4.1: The 1,300% Pediatric Surge

The Record: National and State Poison Control Audits (2017-2026).

The Summary: Accidental exposures in children under 6 skyrocketed from 207 cases in 2017 to over 3,000 annually by 2024. Clinical presentations include coma, respiratory depression, and near-cardiac arrest caused by "beaker-slurry" synthetics.

Link:

Geisinger Health: 2025 Pediatric Threat Report

EXHIBIT 4.2: The 4-Year-Old Median

The Record: Michigan Poison & Drug Information Center (MiPDC) 2024 Audit.

The Summary: An 800% increase in synthetic cannabinoid cases among minors, with the median victim age being 4 years old. Symptoms include CNS depression and severe tachycardia.

Link:

MiPDC: Synthetic Cannabinoid Data Summary

EXHIBIT 4.3: Confirmed Fatalities (D.C. OCME)

The Record: Office of the Chief Medical Examiner (OCME) Death Audit.

The Summary: 39 confirmed deaths specifically linked to synthetic cannabinoid toxicity. Deaths increased by 100% in 2022 alone as "gas station" isomers flooded the market under political cover.

Link:

D.C. OCME: Forensic Fatality Report

EXHIBIT 4.4: The Price of the Loophole

The Record: Commonwealth of Virginia vs. Clements (2022 Fatality).

The Summary: The forensic death of 4-year-old Tanner Clements, linked directly to "Delta-8-THC Toxicity" from a legally purchased "hemp-derived" product. This case proves "Hemp-Derived" is a marketing term, not a safety standard.

Link:

CBS News: The Tanner Clements Fatality Record

EXHIBIT 4.5: Federal Health Advisory

The Record: CDC Clinical Warning Archive.

The Summary: Federal confirmation that synthetic cannabinoids cause seizures, stroke, and kidney failure. This is the "Liberty" the Grandstanders are protecting for their donors.

CDC Archive: Synthetic Cannabinoid Health Risks

“Natural products are not linked to any of this. The DNA doesn’t lie.”

- Bill Polyniak, The 37th Parallel Audit